Fundraising through the Issuance of the 6th to 8th Series of Stock Acquisition Rights
First written in FY2019-Q2. 3 of 5 entries say "Advanced", first in FY2019-Q3. Latest entry: FY2021.
7 other companies' latest entry also says "Other".
- FY2021Stock acquisition rights expiredAnnual report
「The number of shares underlying the Sixth, Seventh and Eighth Series Stock Acquisition Rights declined by 1,369,500, 1,065,000 and 923,100, respectively, during the current consolidated fiscal year, leaving no balance at the end of the fiscal year.」
The balances of the former Sixth to Eighth Series Stock Acquisition Rights fell to zero following their expiration. - FY2020-Q1AdvancedAnnual report
「During the first quarter of the current consolidated period, the main factor was an increase of ¥300 million each in share capital and the capital reserve resulting from the exercise of stock acquisition rights as stock options. As a result, at the end of the first quarter of the current consolidated accounting period, share capital was ¥2,880 million and capital surplus was ¥2,833 million.」
The exercise of stock acquisition rights increased the number of issued shares by 1,128,600 between March and May 2019, and increased share capital and the capital reserve by ¥300 million each. - FY2019AdvancedAnnual report
「1 March 2018–28 February 2019 501,600 46,807,500 415,817 2,580,425 415,817 2,540,425」
The number of issued shares increased by 501,600 through the exercise of stock acquisition rights and other transactions, while share capital and the capital reserve increased by ¥416 million each. Following the issuance of the Sixth to Eighth Series Stock Acquisition Rights, the number of shares underlying the rights declined by 300,000. - FY2019-Q3AdvancedAnnual report
「During the first nine months of the current consolidated period, the main factors were increases of ¥416 million each in share capital and capital surplus resulting from the exercise of stock acquisition rights, and a ¥428 million decrease in capital surplus resulting from the additional acquisition of shares in consolidated subsidiary 株式会社メディコマ. As a result, at the end of the third quarter of the current consolidated accounting period, share capital was ¥2,580 million and capital surplus was ¥2,616 million.」
The exercise of stock acquisition rights increased share capital and capital surplus by ¥416 million each, and the number of issued shares increased by 386,400 during the third quarter. - FY2019-Q2First statedAnnual report
「The stock acquisition rights issued during the consolidated second quarter are as follows.」
Pursuant to resolutions adopted on 14 August 2018, the Company issued the Sixth, Seventh and Eighth Series Stock Acquisition Rights. The total number of underlying shares was 3,657,600, and the exercise period for each series was from 31 August 2018 to 28 August 2020. Proceeds from the issuance of the stock acquisition rights were ¥197 million.